Home Featured Page 211

Featured

Latest

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for...

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for...

Wesana Health Provides Strategic and Operational Updates

Field Trip Receives Notice of Allowance for US Patent Application Covering...

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary...

PharmaDrug Announces Resignation of Director

PT284 – Jonathan Sabbagh – Ketamine-Assisted Psychotherapy and Collaborative Care

Mydecine to Launch Special Access Support and Supply Program in Canada...

MYND Life Sciences Announces Collaborative Research Agreement with the University of...

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for...

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for...

Wesana Health Provides Strategic and Operational Updates

Field Trip Receives Notice of Allowance for US Patent Application Covering...

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

EDITOR PICKS

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and...

Why Perimenopause Belongs in Psychedelic Research

The Psychedelic Practitioner Issue 6: Preparedness (People)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY